PORTLAND INVESTMENT COUNSEL INC.
Position in TLX — Telix Pharmaceuticals Ltd
CIK 1081668
BURLINGTON, A6
Position in TLX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$3,069,286
+$521,752 QoQ
Shares Held
266,200
0.0% QoQ
Ownership
0.079%
of shares outstanding
% of Portfolio
0.86%
of 13F equity value
Holder Rank
#3
of 61 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PORTLAND INVESTMENT COUNSEL INC. holds $5,865,331 across 9 Biotechnology names. TLX ranks #1 (52.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TLX |
Telix Pharmaceuticals Ltd
This page
|
266,200 | $3,069,286 | |
| 2 | ONC |
BeOne Medicines Ltd.
|
3,000 | $854,910 | |
| 3 | OLMA |
Olema Pharmaceuticals, Inc.
|
50,000 | $625,500 | |
| 4 | IOVA |
Iovance Biotherapeutics, Inc.
|
130,000 | $540,800 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
654 | $407,795 | |
| 6 | RLAY |
Relay Therapeutics, Inc.
|
10,000 | $187,100 | |
| 7 | ARVN |
Arvinas, Inc.
|
14,000 | $116,340 | |
| 8 | BCYC |
Bicycle Therapeutics PLC
|
15,000 | $63,600 |
All Filings in TLX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,069,286 | 266,200 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $2,547,534 | 266,200 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,993,838 | 266,200 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $1,224,960 | 128,000 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||